Roche's Tecentriq Cuts Bladder Cancer Risks by Up to 41% in Groundbreaking Study

Roches Tecentriq, an Atezolizumab-based treatment, significantly reduces risks associated with bladder cancer, demonstrating a groundbreaking advancement in post-surgery therapy through a ctDNA-guided approach.

• In the phase III IMvigor011 study, Roches Atezolizumab reduced the risk of death by 41% among patients with muscle-invasive bladder cancer compared to placebo.
• The study also showed a 36% reduction in the risk of disease recurrence or death, emphasizing the effectiveness of Atezolizumab in bladder cancer treatment.
• IMvigor011 is notable for pioneering a ctDNA-guided approach to post-surgery treatment, marking a significant advancement in the phases of clinical research for bladder cancer.